Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Francesco Perrone, Diego Cortinovis et al.|Journal of Clinical Oncology|2018Cited by 70
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trialStefano Cascinu, Francesco Perrone, Rossana Berardi et al.|European Journal of Cancer|2021Cited by 17
BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver functionGennaro Daniele, Bruno Daniele, Clorinda Schettino et al.|Hepatoma Research|2021Cited by 5
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITYValentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|IRIS UNIMORE (University of Modena and Reggio Emilia)|2007Cited by 4
Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)Francesco Gelsomino, Andrea Ardizzoni, Marcello Tiseo et al.|Annals of Oncology|2018Cited by 2